Author

Oluwaseun Aina

Institution: Regeneron (United States)

Observed institution: Regeneron (United States)

OpenAlex ID: A5059020900

Abstract CT013: Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma

2023 · Attaya Suvannasankha, Prashant Kapoor, et al. · Cancer Research · 14

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

2025 · Robert Orlowski, Mansi Shah, et al. · Blood · 9

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

2023 · Paula Rodriguez Otero, Maria-Victoria Mateos, et al. · Blood · 4

Adrenal Psychosis, A Diagnostic Challenge

2013 · Oluwaseun Aina · Endocrinology & Metabolic Syndrome · 3

First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.

2026 · Ashutosh D. Wechalekar, Hans C. Lee, et al. · Journal of Clinical Oncology

Linvoseltamab (LINVO) Monotherapy in Patients (pts) with Newly Diagnosed (ND) Multiple Myeloma (MM): Initial Dose-Escalation Results from the Window of Opportunity LINKER-MM4 Trial

2025 · Christopher Ferreri, Mansi Shah, et al. · Clinical Lymphoma Myeloma & Leukemia

Pb2144: Trial in Progress: a Phase 1/2 Window of Opportunity Study of the Bcmaxcd3 Bispecific Antibody Linvoseltamab in Previously Untreated Patients With Symptomatic Multiple Myeloma

2023 · Christopher J. Ferreri, Steven Quatela, et al. · HemaSphere

When All Psychotropic Combinations Fail, Revisit Organic Causes of Psychiatric Problems

2013 · Oluwaseun Aina

Works count: 8

Citation count: 30

H-index: 3

I10-index: 1